Full Press Release Details
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b Retain Trial of ACI 35 030 in Preclinical Alzheimer s Disease.
ACIU
AC Immune Receives Second Milestone Payment Following Progress in Phase 2b Retain Trial of ACI 35 030 in Preclinical Alzheimer s Disease
Key Takeaway: AC Immune Receives Second Milestone Payment Following Progress in Phase 2b Retain Trial of ACI 35 030 in Preclinical Alzheimer s Disease